Zobrazeno 1 - 10
of 214
pro vyhledávání: '"Brendan D, Curti"'
Autor:
Craig P. Collins, Lam T. Khuat, Gail D. Sckisel, Logan V. Vick, Christine M. Minnar, Cordelia Dunai, Catherine T. Le, Brendan D. Curti, Marka Crittenden, Alexander Merleev, Michael Sheng, Nelson J. Chao, Emanual Maverakis, Spencer R. Rosario, Arta M. Monjazeb, Bruce R. Blazar, Dan L. Longo, Robert J. Canter, William J. Murphy
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The thymus is the central organ involved with T-cell development and the production of naïve T cells. During normal aging, the thymus undergoes marked involution, reducing naïve T-cell output and resulting in a predominance of long-lived memory T c
Externí odkaz:
https://doaj.org/article/1e288536df9248b1a327800dd3a6007e
Autor:
Thomas F Gajewski, John A Thompson, Sanjay Goel, Brendan D Curti, Elisabeth I Heath, Olivier Rixe, David C Smith, Celine Jacquemont, Tycel Phillips, Martin Gutierrez, Sahar Ansari, Andrew L Coveler, Svetomir N Markovic, Timothy M Kuzel, Amitkumar N Mehta, David L Bajor, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt, Juneko E Grilley-Olson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, an immune-activating tumor necrosis factor receptor superfamily member. SEA-CD40 exhibits enhanced binding to activating FcγRIIIa, po
Externí odkaz:
https://doaj.org/article/997d45d0420040f2a6abbe4400763c7d
Autor:
Christy Ralph, Sumati Gupta, Matthew Zibelman, Brendan D Curti, Kevin J Harrington, Steven J O'Day, Andrew G Hill, David C Campbell, Gavin M Wright, David E Gerber, Jonathan E Rosenberg, Jaime R Merchan, Charles M Rudin, Hardev S Pandha, Wallace L Akerley, Daphne Day, Timothy D Clay, Ross R Jennens, Yixin Ren, Emmett V Schmidt, Lisa Guttman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 1 (2023)
Background Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors.Methods Patients had advanced non-small cell lung cancer
Externí odkaz:
https://doaj.org/article/07dff5f507bc4d64bce5f819f24c264d
Autor:
Gregory A Daniels, Sigrun Hallmeyer, Mark Grose, Jon Richards, Mark Faries, Brendan D Curti, Kim A Margolin, Yiwei Zhang, Lynn Feun, Anlong Li, John R Hyngstrom, Robert H I Andtbacka
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background Intratumoral administration of V937, a bioselected, genetically unmodified coxsackievirus A21, has previously demonstrated antitumor activity in patients with advanced melanoma as monotherapy and in combination with the programmed cell dea
Externí odkaz:
https://doaj.org/article/9f10038a20424ab08d0ae2615bc3df12
Autor:
Tamson V. Moore, Gina M. Scurti, Matthew DeJong, Siao-Yi Wang, Annika V. Dalheim, Courtney R. Wagner, Kelli A. Hutchens, Jodi J. Speiser, Constantine V. Godellas, Chris Fountain, Jessica Fleser, Tarsem Moudgil, Mallory Thomas, David Murray, Brendan D. Curti, Joseph I. Clark, Bernard A. Fox, Michael I. Nishimura
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 352-363 (2021)
T cells that are gene-modified with tumor-specific T cell receptors are a promising treatment for metastatic melanoma patients. In a clinical trial, we treated seven metastatic melanoma patients with autologous T cells transduced to express a tyrosin
Externí odkaz:
https://doaj.org/article/89a5e7e4a04a46e287fbf116f56ea560
Autor:
Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo B. Bifulco, Brady Bernard, Rom S. Leidner, Brendan D. Curti, Bernard A. Fox, Walter J. Urba, R. Bryan Bell, Andrew D. Weinberg
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Different neoadjuvant therapies have been proposed to improve immunotherapy for cancer treatment. Here, the authors perform a phase Ib clinical trial where an agonist OX40 antibody provided prior to surgery is well tolerated and increases proliferati
Externí odkaz:
https://doaj.org/article/e0c32b2dd76c42039a82409b6dfffcd3
Autor:
William L Redmond, Walter J Urba, John Cha, Yoshinobu Koguchi, Brendan D Curti, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, Brian D Piening
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/76e873d352b1483a8641f7e468b7a2f9
Autor:
Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba, Rom S. Leidner
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature. However, specific cases were rarely described until 2018, when a wave of reports surfaced.
Externí odkaz:
https://doaj.org/article/7853dedc4aa84563960981541b8d046a
Autor:
Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels, Brendan D. Curti, Sapna P. Patel, Shernan G. Holtan, Gerald P. Miletello, Mayer N. Fishman, Rene Gonzalez, Joseph I. Clark, John M. Richart, Christopher D. Lao, Scott S. Tykodi, Ann W. Silk, David F. McDermott
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable resp
Externí odkaz:
https://doaj.org/article/2501d6126ef24a80bcbed81058801563
Autor:
Lisa A. Kottschade, Gregory Russell Pond, Anthony J. Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J. Hauke, Brendan D. Curti, Sarah Schober, Mohammed M. Milhem, Matthew Stephen Block, Tina Hieken, Robert R. McWilliams
Publikováno v:
Clinical Cancer Research. :OF1-OF6
Purpose: Mucosal melanoma is a rare, aggressive form of melanoma with extremely high recurrence rates despite definitive surgical resection with curative intent. Currently there is no consensus on adjuvant therapy. Data on checkpoint inhibitors for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f17632ed77ac64bf22946772a46e3ef1
https://doi.org/10.1158/1078-0432.ccr-22-3207
https://doi.org/10.1158/1078-0432.ccr-22-3207